<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/24/regulus-therapeutics-nasdaqrgls-rating-increased-to-buy-at-zacks-investment-research.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-24T11:47:18+00:00"/>
    <meta property="og:title" content="Regulus Therapeutics (NASDAQ:RGLS) Rating Increased to Buy at Zacks Investment Research"/>
    <meta property="og:description" content="Zacks Investment Research upgraded shares of Regulus Therapeutics (NASDAQ:RGLS) from a hold rating to a buy rating in a research note published on Wednesday morning, Zacks.com reports. The firm currently has $0.75 price objective on the biopharmaceutical company’s stock. According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs […]"/>
  </head>
  <body>
    <article>
      <h1>Regulus Therapeutics (NASDAQ:RGLS) Rating Increased to Buy at Zacks Investment Research</h1>
      <address><time datetime="2019-11-24T11:47:18+00:00">24 Nov 2019, 11:47</time> by <a rel="author" href="https://www.thecerbatgem.com/author/scott" target="_blank">Scott Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/regulus-therapeutics-inc-logo.jpg"/>
      </figure>
      <p><a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> upgraded shares of Regulus Therapeutics (NASDAQ:RGLS) from a hold rating to a buy rating in a research note published on Wednesday morning, <a href="https://www.zacks.com//">Zacks.com</a> reports. The firm currently has $0.75 price objective on the biopharmaceutical company’s stock.</p>
      <p>According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “</p>
      <p>RGLS has been the topic of several other research reports. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=RGLS">ValuEngine</a> raised Regulus Therapeutics from a sell rating to a hold rating in a research note on Thursday, August 1st. Needham &amp; Company LLC reissued a hold rating on shares of Regulus Therapeutics in a research note on Tuesday, August 13th. HC Wainwright started coverage on Regulus Therapeutics in a research note on Friday, September 6th. They issued a buy rating and a $2.00 price objective on the stock. Finally, Wedbush reissued a hold rating and issued a $1.00 price objective on shares of Regulus Therapeutics in a research note on Thursday, November 14th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $1.31.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/RGLS/price-target/">RGLS stock</a> traded up $0.03 during midday trading on Wednesday, reaching $0.69. 175,100 shares of the company traded hands, compared to its average volume of 63,678. Regulus Therapeutics has a 52-week low of $0.50 and a 52-week high of $1.86. The firm has a market capitalization of $13.77 million, a price-to-earnings ratio of -0.12 and a beta of 1.46. The business has a 50 day moving average of $0.67 and a 200-day moving average of $0.88.</p>
      <p>Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.26). Regulus Therapeutics had a negative return on equity of 163,378.48% and a negative net margin of 325.85%. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. As a group, equities research analysts forecast that Regulus Therapeutics will post -0.86 EPS for the current year.</p>
      <p>A number of large investors have recently made changes to their positions in RGLS. NEA Management Company LLC boosted its position in Regulus Therapeutics by 124.1% during the 2nd quarter. NEA Management Company LLC now owns 2,052,455 shares of the biopharmaceutical company’s stock valued at $2,566,000 after acquiring an additional 1,136,704 shares in the last quarter. EcoR1 Capital LLC bought a new stake in Regulus Therapeutics during the 2nd quarter valued at $1,389,000. Samsara BioCapital LLC bought a new stake in Regulus Therapeutics during the 2nd quarter valued at $1,131,000. Finally, CVI Holdings LLC bought a new stake in Regulus Therapeutics during the 2nd quarter valued at $568,000. 45.05% of the stock is currently owned by institutional investors.</p>
      <p>
        <b>About Regulus Therapeutics</b>
      </p>
      <p>Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.</p>
      <p>Read More: <a href="https://www.marketbeat.com/financial-terms/what-is-diluted-earnings-per-share/">Diluted Earnings Per Share</a></p>
      <p>
        <a href="https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&amp;ADID=AMERBMN_CONTENT_ZER&amp;skip_rpt_name_check=skip_rpt_name_check&amp;t=RGLS">Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)</a>
      </p>
      <p>For more information about research offerings from Zacks Investment Research, visit <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks.com</a></p>
    </article>
  </body>
</html>